ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
about
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia AAntidrug Antibodies: B Cell Immunity Against TherapyManagement of hemophilia in Korea: the past, present, and future.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.New findings on inhibitor development: from registries to clinical studies.Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study).How I manage patients with inherited haemophilia A and B and factor inhibitors.
P2860
Q26738507-4E38788A-924F-424F-9555-9AA507D7E3A5Q28082303-0A2877CA-DFA9-438E-BD44-6CF6DCB7ED9BQ34302456-6CF9C6CA-0884-43AA-BA2F-A70440248E71Q37185097-AFE5D1CC-B51F-4490-B207-7E01D8FA8B6EQ39042987-C308B71D-D976-4D0F-9BA1-72441897A235Q40638146-341DABBA-86E7-4FFC-92C4-9D1D9E8BEAE0Q48359988-D9B9D34E-52CE-4E53-8558-8AAA3C1D4401
P2860
ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
ITI choice for the optimal man ...... pharmacoeconomic perspective.
@en
type
label
ITI choice for the optimal man ...... pharmacoeconomic perspective.
@en
prefLabel
ITI choice for the optimal man ...... pharmacoeconomic perspective.
@en
P2093
P2860
P356
P1433
P1476
ITI choice for the optimal man ...... pharmacoeconomic perspective.
@en
P2093
C M Kessler
J Oldenburg
S K Austin
P2860
P356
10.1111/HAE.12466
P478
20 Suppl 6
P577
2014-09-01T00:00:00Z